Search hospitals > Texas > Dallas
Mary Crowley Cancer Research
Claim this profileDallas, Texas 75230
Global Leader in Solid Tumors
Global Leader in Tumors
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
290 reported clinical trials
6 medical researchers
Summary
Mary Crowley Cancer Research is a medical facility located in Dallas, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Mary Crowley Cancer Research is involved with conducting 290 clinical trials across 163 conditions. There are 6 research doctors associated with this hospital, such as Minal Barve, MD, James Strauss, Douglas Orr, MD, and Reva Schneider.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
Minal Barve, MDMary Crowley Cancer Research3 years of reported clinical research
Expert in Tumors
Expert in Solid Tumors
45 reported clinical trials
70 drugs studied
James StraussMary Crowley Cancer Research3 years of reported clinical research
Expert in Tumors
Studies Solid Tumors
25 reported clinical trials
48 drugs studied
Douglas Orr, MDMary Crowley Cancer Research3 years of reported clinical research
Expert in Solid Tumors
Studies Tumors
17 reported clinical trials
31 drugs studied
Reva SchneiderMary Crowley Cancer Research2 years of reported clinical research
Studies Tumors
Studies Solid Tumors
9 reported clinical trials
11 drugs studied
Clinical Trials running at Mary Crowley Cancer Research
Breast Cancer
Solid Tumors
Ovarian Cancer
Non-Small Cell Lung Cancer
Tumors
Endometrial Cancer
Prostate Cancer
Cancer
Lung Cancer
Colorectal Cancer
Bria-IMT + CPI
for Advanced Breast Cancer
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Recruiting2 awards Phase 36 criteria
PRO1184
for Cancer
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Recruiting1 award Phase 1 & 27 criteria
BG-68501 + Fulvestrant
for Breast Cancer
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion) and Part 2 (dose expansion).
Recruiting1 award Phase 16 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Mary Crowley Cancer Research?
Mary Crowley Cancer Research is a medical facility located in Dallas, Texas. This center is recognized for care of Solid Tumors, Tumors, Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Mary Crowley Cancer Research is involved with conducting 290 clinical trials across 163 conditions. There are 6 research doctors associated with this hospital, such as Minal Barve, MD, James Strauss, Douglas Orr, MD, and Reva Schneider.